Physician profile
Mary Kay Koenig
NPI 1881895993
$170,775.25
in general payments reported to CMS, 2019-2025
29 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $13K · 2021: $6,290 · 2022: $13K · 2023: $27K · 2024: $20K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $27K · Travel and Lodging: $10K · Food and Beverage: $3,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,470.00 |
| Consulting Fee | $27,450.00 |
| Travel and Lodging | $10,163.97 |
| Food and Beverage | $3,866.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68,175.52 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $50,399.38 | 2022-2025 | Epidiolex |
| Immedica Pharma US, INC. | $20,190.01 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $12,660.64 | 2022-2025 | Nuplazid, Daybue |
| Greenwich Biosciences, INC. | $8,371.34 | 2020-2021 | |
| Ucb Sa | $3,200.00 | 2024-2025 | |
| H. Lundbeck A S | $2,083.61 | 2024 | |
| Ptc Therapeutics, INC. | $2,029.57 | 2022-2023 | |
| Ucb, INC. | $1,194.41 | 2022-2025 | Fintepla, Briviact |
| Zogenix INC. | $1,000.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $516.67 | 2022 | |
| Biogen, INC. | $158.91 | 2021-2025 | Skyclarys |
| Upsher-Smith Laboratories LLC | $135.20 | 2019-2024 | |
| Eisai INC. | $127.79 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.82 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $121.82 | 2023 | Dojolvi |
| Neurocrine Biosciences, INC. | $80.60 | 2023-2024 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $52.63 | 2023 | |
| Pyros Pharmaceuticals, INC. | $29.90 | 2024 | Vigpoder |
| Bioventus LLC | $24.79 | 2022 | |
| Supernus Pharmaceuticals, INC. | $22.49 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $22.16 | 2024 | Spritam |
| Neurelis, INC. | $19.39 | 2023 | Valtoco |
| Livanova USA, INC. | $16.24 | 2021 | |
| Alfasigma USA, INC. | $14.22 | 2021 | |
| Aucta Pharmaceuticals, INC. | $3.14 | 2025 | Motpoly Xr |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kay Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.